EarningsQ3 2026 Earnings Report
MX:ARWR Q3 2026 EPS Results
Actual EPS-$24.49
Consensus EPS-$22.99
Beat/MissMissed by -$1.49
One Year Ago EPS-$22.69
MX:ARWR Q3 2026 Revenue Results
Actual Revenue$1.35B
Expected Revenue$795.32M
Beat/MissBeat by +$559.59M
YoY Revenue Growth+171.02%
Earnings Announcement Details
QuarterQ3 2026
Date08/04/2026
TimeAfter Close
Conference CallTuesday, August 4, 2026
MX:ARWR Upcoming Earnings
Arrowhead Pharmaceuticals's next earnings date is estimated for November 30, 2026, based on past reporting schedules.
Q3 2026 Earnings Call Audio
MX:ARWR Q3 2026 Earnings Call
0:00 / 0:00
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call was decidedly positive on clinical and strategic fronts: landmark Phase III SHASTA-3/4 results (deep TG reductions and major reductions in acute pancreatitis), broad regulatory approvals, accelerating commercial traction in FCS, strong partnership revenue and a robust pipeline with multiple near-term data catalysts. Offsetting items include increased net losses and higher operating spend as Arrowhead scales R&D and commercial infrastructure, a sizable near-term cash payment for a priority review voucher ($215M), and the fact that commercial product revenues remain small today. Overall, management portrayed the financial investments as deliberate and tied to significant near-term derisking and value-creation events.Company Guidance
Positive Phase III SHASTA-3 and SHASTA-4 Results
Both pivotal trials met the primary endpoint and every prespecified secondary endpoint. Median triglyceride reductions from baseline were 79% (SHASTA-3) and 81% (SHASTA-4) at month 12, demonstrating deep, durable and consistent TG lowering across studies.
Large Reduction in Acute Pancreatitis Events
Pooled analysis showed a 78% reduction in cumulative acute pancreatitis (AP) events versus placebo across the broad sHTG population; in the highest-risk subgroup (TG >880 mg/dL with prior AP), AP events were reduced by 100% versus placebo.
Favorable Safety and Tolerability Profile
No new safety signals reported across SHASTA-3/4 and prior studies: no clinically meaningful liver enzyme changes, no hypersensitivity cases, no thrombocytopenia signal and no statistically significant difference in mean liver fat (MRI-PDFF subgroup).
Regulatory and Approval Momentum
REDEMPLO now has approvals across five geographies (U.S., Canada, China, Australia, European Commission). Arrowhead acquired a priority review voucher to potentially shorten U.S. FDA review from ~10 months to ~6 months for the sNDA.
Commercial Launch Traction for REDEMPLO (FCS)
U.S. launch momentum: prescriptions more than doubled quarter-on-quarter; supported >400 unique prescribers; ongoing weekly run rate ~20–30 new prescriptions/week. U.S. WAC is $45,000 per patient per year under the One REDEMPLO pricing model.
Revenue Growth and Partnership Income
Quarterly revenue rose to ~$75 million from $28 million in the prior year quarter (+~168%), driven by collaboration/license revenue (Sarepta, Novartis, Madrigal, Sanofi) and early commercial REDEMPLO sales. Received $25M upfront from Madrigal; recognized ~$26M from Sarepta and ~$20M from Novartis in the quarter.
Robust Pipeline Progress and Near-Term Data Catalysts
Key advances: ARO-INHBE (single 400 mg dose produced mean maximum reductions >85% and a 44% placebo-adjusted liver fat reduction in a subgroup); Zodasiran YOSEMITE Phase III in HoFH fully enrolled at 70 patients (vs planned 60); ARO-DIMER-PA and ARO-MAPT top-line data expected in September; plan to have 23 drug candidates in clinical trials by year-end.
Strong Balance Sheet and Financial Flexibility
Cash and investments totaled approximately $1.6 billion as of June 30, 2026, providing runway to support clinical development, commercialization and strategic initiatives.
MX:ARWR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed